Pacific Edge shares gain 6.5% on first commercial deal in Singapore

Pacific Edge chief executive David Darling says Singapore "remains an exciting proposition for Pacific Edge."

Pacific Edge shares rose 6.5 percent after the cancer diagnostics firm signed its first commercial deal to supply its suite of Cxbladder tests in Singapore.

The stock increased 2.5 cents to 41 cents after the Dunedin-based company said it reached a commercial agreement with a unit of Raffles Medical Group to use the bladder cancer tests in Singapore, the company said in a statement. Under the deal, the Raffles unit will coordinate specimen collection, shipping and reporting of Cxbladder tests for the medical firm's patients in the Asian city.

"We are delighted to work with the prestigious Raffles Medical Group in Singapore and whilst this is a relatively small commercial proposition for Pacific Edge, it offers a significant stepping stone into the Raffles Medical Group across South East Asia," Pacific Edge chief executive David Darling said. "The region remains an exciting proposition for Pacific Edge with approximately 9,500 urologists and an estimated 1.8 million potential tests."

Pacific Edge raised $21.3 million in a discounted rights issue last year, which it said left it flush enough to fund the operation until it starts breaking even in 2019.

The company's international ambitions have rested largely on breaking into the US market, although that's taken longer than expected, and started eyeing Singapore as a gateway to South East Asia in 2015.

Raffles operates in 13 cities across Singapore, China, Japan, Vietnam and Cambodia, and is in the only fully integrated private healthcare operation in Singapore.

(BusinessDesk)


4 · Got a question about this story? Leave it in Comments & Questions below.

This article is tagged with the following keywords. Find out more about MyNBR Tags

Post Comment

4 Comments & Questions

Commenter icon key: Subscriber Verified

All noise

The same noise occurred years ago when they secured the USA deal but it hasn't delivered

The recent press releases by this company create great humour

Reply
Share
  • 0
  • 0

Deal could be for 1 test, or 1.8M tests. Who knows with this company and its serial offending of keeping shareholders in total darkness with a distinct lack of forecasting!

At the current overvalued mcap of $200M+ on very low revenue, It's USA or bust. No ifs, ands or buts...

Reply
Share
  • 0
  • 0

Ah but there are committed institutions in there supporting the company and the numerous capital raisings (undertaken at ever lower offer prices) to fund through to success in the US.

Or is it a case that they have no choice as they now own too much of the company - in too deep and too big an exposure to allow the company to fail?

Reply
Share
  • 0
  • 0

Good point Moose

From current form it's likely to be yet another failure - so at best tests in the thousands not millions.

Reply
Share
  • 0
  • 0

Post New comment or question

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

NZ Market Snapshot

Forex

Sym Price Change
USD 0.7386 0.0000 0.00%
AUD 0.9339 0.0000 0.00%
EUR 0.5955 0.0000 0.00%
GBP 0.5265 0.0000 0.00%
HKD 5.7785 0.0000 0.00%
JPY 78.3770 0.0000 0.00%

Commods

Commodity Price Change Time
Gold Index 1346.5 -6.690 2018-02-16T00:
Oil Brent 64.9 0.510 2018-02-16T00:
Oil Nymex 61.8 0.390 2018-02-16T00:
Silver Index 16.7 -0.090 2018-02-16T00:

Indices

Symbol Open High Last %
NASDAQ 7236.5 7303.3 7256.4 -0.23%
DJI 25165.9 25432.4 25200.4 0.08%